Zheng Li

机构：Xuzhou Medical College, Hunan Entry-Exit Inspection and Quarantine Bureau · ORCID：0000-0001-8067-9700

发表论文 194 篇 · 总被引 3498 次 · h-index 34

代表论文

• Discovery of First-in-Class FXR and HSD17B13 Dual Modulator for the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease (2025 · Journal of Medicinal Chemistry · 被引 16)
• Biased Opioid Receptor Agonists: Balancing Analgesic Efficacy and Side-Effect Profiles (2025 · International Journal of Molecular Sciences · 被引 14)
• Discovery of LH10, a novel fexaramine-based FXR agonist for the treatment of liver disease (2024 · Bioorganic Chemistry · 被引 13)
• Jiawei Dachaihu decoction protects against mitochondrial dysfunction in atherosclerosis (AS) mice with chronic unpredictable mild stress (CUMS) via SIRT1/PGC-1α/TFAM/LON signaling pathway (2024 · Journal of Ethnopharmacology · 被引 11)
• Design, synthesis, and biological evaluation of first-in-class FABP1 inhibitors for the treatment of NASH (2024 · European Journal of Medicinal Chemistry · 被引 10)
• Discovery of Highly Potent, Selective, and Liver-Targeting HSD17B13 Inhibitor with Robust In Vivo Anti-MASH Activity (2025 · Journal of Medicinal Chemistry · 被引 9)